Advanced Search
Article Contents
ABOUT THIS ARTICLE
The Innovation Drug Discovery > 2026 Vol. 1 > No. 2 > 100018
Next Article Previous Article
LETTER   Open Access     Cite

Tuning complex life networks: Single-molecule multi-target strategies transforming metabolic disease treatment

  • 1.

    Department of Medicinal Chemistry, State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Shandong Key Laboratory of Druggability Optimization and Evaluation for Lead Compounds, School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, Jinan 250012, China

  • 2.

    State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Xue Yuan Rd. 38, Beijing 100191, China

  • 3.

    State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine (Tianjin Institute of Pharmaceutical Research), Tianjin 300301, China

  • 4.

    These authors contributed equally to this work

More Information
The Innovation Drug Discovery  1(2),  https://doi.org/10.59717/j.xinn-drugdisc.2026.100018  |  Cite this article
    • FullText(HTML)
  • 加载中
    • REFERENCES
  • [1] Scotti L., Monteiro A. F. M., de Oliveira Viana J., et al. (2019). Multi-Target Drugs Against Metabolic Disorders. Endocr Metab Immune Disord Drug Targets 19:402−418. DOI:10.2174/1871530319666181217123357

    View in Article CrossRef Google Scholar

    [2] Zhang Z., Shi X., Wu T., et al. (2025). Discovery of multi-target anti-gout agents from Eurycoma longifolia Jack through phenotypic screening and structural optimization. Nature communications 16:7430. DOI: 10.1038/s41467-025-62645-6

    View in Article Google Scholar

    [3] Prasad A., Arora A., Arora A., et al. (2026). Exposure-adjusted safety and efficacy of GLP-I and GLP-1/GIP receptor agonists compared with non-GLP-I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects. British journal of clinical pharmacology, Published online March 27:2026. DOI:10.1002/bcp.70515

    View in Article CrossRef Google Scholar

    [4] Jastreboff A. M., le Roux C. W., Stefanski A., et al. (2025). Tirzepatide for Obesity Treatment and Diabetes Prevention. The New England Journal of Medicine 392:958−971. DOI:10.1056/NEJMoa2410819

    View in Article CrossRef Google Scholar

    [5] Liskiewicz D., Novikoff A., Khalil A., et al. (2026). GLP-1R–GIPR–PPARα/γ/δ quintuple agonism corrects obesity and diabetes in mice. Nature 653:776−785. DOI:10.1038/s41586-026-10619-z

    View in Article CrossRef Google Scholar

    [6] Sun Y., Liu S., Chen L., et al. (2025). AI-driven discovery of dual antiaging and anti-AD therapeutics via PROTAC target deconvolution of a super-enhancer–regulated axis. Science Advances 11:eadz9283. DOI:10.1126/sciadv.adz9283

    View in Article CrossRef Google Scholar

    [7] Lillich F. F., Imig J. D. and Proschak E. (2021). Multi-Target Approaches in Metabolic Syndrome. Frontiers in pharmacology 11:554961. DOI:10.3389/fphar.2020.554961

    View in Article CrossRef Google Scholar

    [8] Su Q., Gou Q., Zhang H., et al. (2026). LaMGen: LLM-based 3D molecular generation for multi-target drug design. Nature communications 17:5091. DOI:10.1038/s41467-026-71737-w

    View in Article CrossRef Google Scholar

    [9] Nguyen V. T. D., Pham P. and Hy T. S. (2026). Enabling multi-target drug discovery through latent evolutionary optimization and synthesis-aware prioritization (EVOSYNTH). Communications chemistry 9:133. DOI:10.1038/s42004-026-01945-4

    View in Article CrossRef Google Scholar

    [10] Ravikumar B. and Aittokallio T. (2018). Improving the efficacy-safety balance of polypharmacology in multi-target drug discovery. Expert opinion on drug discovery 13:179−192. DOI:10.1080/17460441.2018.1413089

    View in Article CrossRef Google Scholar

    • Cited by

  • Cite this article:

    Jiang Y., Meng W., Shi X., et al. (2026). Tuning complex life networks: Single-molecule multi-target strategies transforming metabolic disease treatment. The Innovation Drug Discovery 1:100018. https://doi.org/10.59717/j.xinn-drugdisc.2026.100018
    Jiang Y., Meng W., Shi X., et al. (2026). Tuning complex life networks: Single-molecule multi-target strategies transforming metabolic disease treatment. The Innovation Drug Discovery 1:100018. https://doi.org/10.59717/j.xinn-drugdisc.2026.100018

Welcome!

To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.

PDF
Figures(1)    

Share

  • Share the QR code with wechat scanning code to friends and circle of friends.

Article Metrics

Article views(264) PDF downloads(83)

Relative Articles

Cited by

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return

    {{newsColumn.name}}

    {{newsColumn.name}}

    Stay connected

    {{newsColumn.name}}

    Website copyright © Innovation Press. Published articles are licensed under CC BY with copyright retained by the authors.